Navigation Links
Medivation Reports Third Quarter 2010 Financial Results and Provides Corporate Update
Date:11/5/2010

motherapy.
  • On track to initiate two new MDV3100 trials in earlier-stage prostate cancer this year: a Phase 2 head-to-head trial comparing MDV3100 with bicalutamide; and a Phase 2 trial in hormone-naive patients.
  • The Proceedings of the National Academy of Sciences (PNAS) published a paper showing the preclinical efficacy of MDV3100 against splice variants, which are mutated forms of the androgen receptor that may be associated with the development of prostate cancer resistance to hormone therapy.

  • Dimebon (latrepirdine)

  • On track to report top-line data from HORIZON in the first half of 2011.  This six-month, randomized, double-blind, placebo-controlled Phase 3 trial is evaluating dimebon's potential benefits on cognition and global function in patients with Huntington disease.

  • Continued to enroll patients in CONCERT and expect to complete patient accrual on November 30, 2010.  This 12-month randomized, double-blind, placebo-controlled Phase 3 clinical trial in patients with mild-to-moderate Alzheimer's disease is evaluating the potential efficacy of dimebon when added to ongoing treatment with donepezil.

  • Corporate

  • Were awarded a $733,000 research and development grant under the Internal Revenue Service's Therapeutic Discovery Project Credit Program.

  • Third Quarter 2010 Financial ResultsRevenue for the third quarter of 2010 was $14.4 million, consisting of partial recognition of the non-refundable up-front payments to date from the Company's corporate partners Pfizer and Astellas.  These payments were recorded as deferred revenue upon receipt and are being recognized as revenue on a straight-line basis over the estimated performance period of the Company's obligations under the applicable collaboration agreement.

    Total operating expenses for the third quarter of 2010 were $21.1 million, compared with $27.6 million for the same
    '/>"/>

    SOURCE Medivation, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Medivation Announces Third Quarter 2010 Financial Results Teleconference and Webcast on November 5, 2010
    2. Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
    3. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
    4. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
    5. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
    6. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
    7. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
    8. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
    9. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
    10. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
    11. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
    (Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
    (Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
    Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
    ... in bone mineral density at the,lumbar spine and ... salmeterol inhalation powder) and salmeterol, - Study ... in patients,with COPD, PHILADELPHIA, Oct. 29 ... three-year study of patients with,Chronic Obstructive Pulmonary Disease ...
    ... Cryoablation ... Treatment Technology, PLEASANTON, ... (ACOSOG) which just initiated a National Cancer,Institute (NCI) funded clinical ... Therapy in the Treatment of Invasive Breast,Carcinoma," has selected the ...
    Cached Medicine Technology:Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 2Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 3NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3
    (Date:12/24/2014)... For chic ladies, new fashionable outfits are necessary ... their Holiday Wish List, Angeldress.co.uk has chosen some ... accent ladies’ holiday wardrobe by launching a promotion on its ... the discount of 80% off, like a cheap suit. , ... company’s chic wedding dresses are among the hottest items in ...
    (Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... regards to the various market dynamics such as the ... assisted arthroscopy, the wait time for U.S. sports medicine, ... medicine market, and the challenges faced by the market. ... http://www.researchmoz.us/global-sports-medicine-market-report-2014-edition-report.html , The report also provides an overview ...
    (Date:12/24/2014)... Plantation, FL (PRWEB) December 24, 2014 ... permanent solution for a tooth replacement. They offer the ... boast several advantages over other forms of tooth replacement. ... not rely on the adjacent teeth for support, and ... many people have been told that they are not ...
    (Date:12/24/2014)... Viejo, California (PRWEB) December 24, 2014 ... release of the ProDenoise from Pixel Film Studios. , “The ... noise or grain in their footage,” said Christina Austin, CEO ... have in any Final Cut Pro X editors toolbox.” , ... film noise or grain in their footage with ProDenoise from ...
    (Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... good news about the experimental Ebola vaccine that U.S. officials ... shows a precursor of that vaccine produced a safe ... of the vaccine, when given to more than 100 Ugandans ... white blood cells that could potentially protect a person against ...
    Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
    ... Amanda Gardner HealthDay Reporter , TUESDAY, April ... the middle ground with its new drug control policy, ... Tuesday, rejects both the harsh "war on drugs" ... the push to legalize illegal drugs. Gil Kerlikowske, ...
    ... HOUSTON - Scientists who developed a technology for identifying and ... have found a way to penetrate the outer membrane and ... the cell. In a paper published today online in ... The University of Texas MD Anderson Cancer Center reports packaging ...
    ... , TUESDAY, April 17 (HealthDay News) -- The ... apparently because of changes in the brain,s white matter, a ... aged 21 to 85, to perform a learning task involving ... that age-related declines in decision-making are associated with the weakening ...
    ... , TUESDAY, April 17 (HealthDay News) -- ... reduce the spread of the AIDS-causing virus, but would ... high risk for HIV infection, according to a new ... to analyze the use of the combination drug tenofovir-emtricitabine ...
    ... By Maureen Salamon HealthDay Reporter , TUESDAY, April ... patients, own tumor cells led to a nearly 50 percent ... the same malignancy that claimed the life of U.S. Sen. ... multicenter trial of about 40 patients with recurrent glioblastoma -- ...
    ... bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell ... in 2006 did not lead to significantly increase survival ... Medicare, a new study by Dana-Farber Cancer Institute researchers has ... 18 Journal of the American Medical Association , a ...
    Cached Medicine News:Health News:White House Drug Policy Shifts Strategy 2Health News:White House Drug Policy Shifts Strategy 3Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 2Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 3Health News:HIV Prevention Pill Cost-Effective for High-Risk Men: Study 2Health News:Brain Tumor Vaccine Shows Promise in Early Trial 2Health News:Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients 2
    ... The SkanWasher 400 is ... microplate washer with built-in ... The individual pressure settings ... very gentle wash to ...
    Lab-Reader...
    Fully automatic NRTL and CE certified microplate reader....
    ... a compact and versatile multilabel ... design allows up to six ... counting, luminescence, absorbance, and fluorescence ... and fluorescence polarization all on ...
    Medicine Products: